CCN5 and sarcopenia: Finally, aged C57BL/6J mice received intramuscular AAV injections to overexpress CCN5 in skeletal muscle, evaluating its therapeutic efficacy against sarcopenia.<h4>Results</h4>Clinical samples included 56 participants (48.2% female; mean age: 63.21 ± 8.76 years).